Introduction
============

Depression, one of the most common psychiatric disorders in the world, is a mood disorder with a high rate of relapse. The World Health Organization (WHO) estimates that more than 320 million individuals of all ages suffer from depression, highlighting this disease as a major contributor to the global burden of disease ([@B85]). Although the precise mechanisms underlying the pathophysiology of depression are currently unknown, accumulating evidence implicate inflammatory processes in the pathophysiology of depression ([@B7]; [@B19]; [@B54]; [@B67]; [@B22]; [@B49]; [@B55]; [@B104]; [@B53]). Meta-analysis demonstrated higher levels of pro-inflammatory cytokines in the blood of drug-free or medicated depressed patients compared to healthy controls ([@B12]; [@B97]; [@B18]; [@B31]). Studies demonstrated elevated gene expression of pro-inflammatory cytokines in the postmortem brain samples from patients with a history of depression ([@B9]; [@B72]). Collectively, it is likely that inflammation plays a key role in the pathophysiology of depression.

Over the past decade, there has been increasing interest in the potential benefits of early intervention for mood disorders. Several lines of evidence suggest that nutrition has a high impact on the development of depression ([@B38]; [@B57]; [@B4]; [@B50]; [@B14]; [@B64]; [@B37]; [@B27]; [@B81]). Recent meta-analyses demonstrated that high intake of fruit, vegetables, fish, and whole grains are associated with a lower risk of depression ([@B35]; [@B39]; [@B69]).

In the review, the author would like to discuss the role of Keap1 \[Kelch-like erythroid cell-derived protein with CNC homology \[ECH\]-associated protein 1)\]-Nrf2 \[Nuclear factor (erythroid 2-derived)-like 2\] system in the pathophysiology of depression since Keap1-Nrf2 system plays a key role in inflammation. Furthermore, we also refer to the clinical significance of natural Nrf2 activator sulforaphane (SFN) as nutritional intervention for mood disorders.

Keap1-Nrf2 System
=================

Nrf2 is the transcription factor with a key role in cellular defense against oxidative stress. It binds to the antioxidant response elements (ARE) located in the promoter region of genes encoding many phase II detoxifying or antioxidant enzymes and related stress-responsive proteins ([@B30]; [@B43]; [@B77]; [@B79]; [@B86]). Under normal conditions, Nrf2 is repressed by Keap1, which is an adaptor protein for the degradation of Nrf2 ([@B77]; [@B79]). During oxidative stress, Nrf2 is de-repressed and activates the transcription of protective genes ([@B77]; [@B79]). Importantly, the Keap1-Nrf2 system plays a role in inflammation-associated pathogenesis ([@B30]; [@B77]; [@B60]; [@B79]; [@B83]; [@B86]). In cancer cells, Nrf2 activation is beneficial and deleterious for the cancer-bearing host, depending on the time (initiation, promotion, and metastasis) and place (cancer cells or microenvironment) ([@B86]).

Nrf2 Activators
===============

Based on the role of Nrf2 in the prevention of a wide variety of pathological conditions, great efforts have been made to isolate from natural sources or develop potent and specific Nrf2 activators ([@B86]). The potent anti-inflammatory and naturally occurring compound sulforaphane (SFN: 1-isothiocyanato-4-methylsulfinylbutane) is an organosulfur compound derived from a glucosinolate precursor glucoraphanin (a glucosinolate, or β-thioglucoside-*N*-hydroxysulfate) (**Figure [1](#F1){ref-type="fig"}**) found in cruciferous vegetables, such as broccoli sprout ([@B105]; [@B16]; [@B34]; [@B29]; [@B15]). It is well known that glucoraphanin can be converted to SFN by the endogenous enzyme, myrosinase ([@B15]). Beneficial effect by SFN is thought to be mediated via activation of the Nrf2 pathway with subsequent up-regulation of phase II detoxification enzymes and antioxidant proteins, through ARE ([@B77]; [@B79]).

![Chemical structure of sulphoraphane (SFN) and its precursor glucoraphanin. Cruciferous vegetables contain glucoraphanin, a glucosinolate derivative of sulforaphane (SFN).](fphar-09-01182-g001){#F1}

TBE-31 \[(±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile\] and MCE-1 \[(±)-3-ethynyl-3-methyl-6-oxocyclohexa-1,4-dienecarbonitrile\] are the novel Nrf2 activators ([@B25]; [@B10]; [@B26]; [@B32]; **Figure [2](#F2){ref-type="fig"}**). Dimethyl fumarate (**Figure [2](#F2){ref-type="fig"}**) is a new oral drug for the treatment of multiple sclerosis, and has neuroprotective effects via Nrf2-dependent antioxidant response ([@B3]; [@B56]). Bardoxolone methyl, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me (**Figure [2](#F2){ref-type="fig"}**), is one of the derivatives of synthetic triterpenoids. Bardoxolone methyl has been used for the treatment of cancer (including leukemia and solid tumors), chronic kidney disease, and other diseases ([@B82]). Clinical trial of bardoxolone methyl is undergoing for diabetic nephropathy in Japan ([@B86]), although its development was paused in the United States due to the occurrence of cardiac complications in patients with end-stage renal disease ([@B66]; [@B8]).

![Chemical structure of Nrf2 activators (TBE-31, MCE-1, dimethyl fumarate, bardoxolone methyl).](fphar-09-01182-g002){#F2}

Effects of Nrf2 Activators on Neurite Outgrowth
===============================================

The neuronal plasticity, including neurite outgrowth and neuroprotection, plays crucial role in the beneficial effect of therapeutic drugs in cellular level ([@B40]; [@B84]). [@B96] reported that SFN increased the number of cell with neurite outgrowth in PC12 cells. Furthermore, the potentiating effects of SFN on NGF-induced neurite outgrowth were blocked by treatment with *Nrf2* siRNA, but not the negative control ([@B96]), suggesting that SFN can potentiate NGF-induced neurite outgrowth via activation of Nrf2.

[@B95] reported that TBE-31 and MCE-1 also potentiated NGF-induced neurite outgrowth in PC12 cells. The *Nrf2* siRNA blocked the potentiating effects of TBE-31 and MCE-1 on neurite outgrowth in PC12 cells. Astragaloside IV is also reported to attenuate lead-induced inhibition of neurite outgrowth through activation of Akt-dependent Nrf2 pathway ([@B98]). Collectively, it is likely that Nrf2 activators can promote neurite outgrowth through Nrf2 activation ([@B90]; [@B95],[@B96]).

Alterations in Keap1-Nrf2 Signaling in Rodents with Depression-Like Phenotype
=============================================================================

Chronic social defeat stress (CSDS) model has been used widely as an animal model of depression ([@B33]; [@B59]; [@B17]). Susceptible mice with depression-like phenotype after CSDS have higher blood levels of pro-inflammatory cytokines \[e.g., tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, and IL-1β\] ([@B101]).

Western blot analysis showed that protein levels of Keap1 and Nrf2 in the CA3, DG, and PFC from mice with depression-like phenotype were significantly lower than those of control mice ([@B96]). In contrast, protein levels of Keap1 and Nrf2 in the CA1 and NAc were not different compared to control ([@B96]). These findings suggest that lower levels of Keap1 and Nrf2 in the CA3, DG, and PFC may be involved in depression-like phenotypes after CSDS.

Learned helplessness (LH) model has been also used as an animal model of depression ([@B33]). In the LH paradigm, approximately 20--40% rats are resilient to inescapable stress ([@B91],[@B92]; [@B89]). LH (susceptible) rats have higher blood levels of IL-6 than control and resilient rats ([@B91]), suggesting that peripheral inflammation may contribute to resilience versus susceptibility to stress. Protein levels of Keap1 and Nrf2 in the PFC and DG of hippocampus from LH (susceptible) rats were lower than control and non-LH (resilient) rats ([@B100]). These results suggest that Keap1-Nrf2 signaling may contribute to stress resilience which is involved in the pathophysiology of major psychiatric disorders ([@B100]).

Alterations in Keap1-Nrf2 Signaling in Samples from Patients with Major Depressive Disorder
===========================================================================================

Major depressive disorder (MDD) patients (*n* = 30) exhibited higher levels of Nrf2 and its regulator Keap1, as well as NF-κB in the cytoplasm of peripheral blood mononuclear cells compared to healthy controls (*n* = 35), suggesting that depression may be characterized by up-regulation of the transcription factor Keap1-Nrf2 ([@B41]). Using genome-wide transcriptional profiling and promoter-based bioinformatic strategies, [@B51] measured leukocyte transcription factor (TF) activity in leukocytes from un-medicated MDD subjects (*n* = 20) versus age- and sex-matched healthy controls (*n* = 20). In leukocytes from un-medicated MDD subjects, the bioinformatic analysis showed an increased transcriptional activity of cAMP response element-binding/activating TF (CREB/ATF) and increased activity of TFs associated with Nrf2. Antidepressant therapy for 8 weeks was associated with significant reductions in depressive symptoms and reduced activity of Nrf2, but not in CREB/ATF activity. By contrast, other transcriptional regulation pathways, including nuclear factor kappa-B cells (NF-κB), early growth response proteins 1-4 (EGR1-4), the glucocorticoid receptor, and interferon-responsive TFs, showed either no difference as a function of disease or treatment. These results suggest that Nrf2 signaling may contribute to MDD by activating immune cell transcriptome dynamics that ultimately may influence motivational and affective processes via circulating mediators ([@B51]).

Postmortem tissue from patients with psychiatric disorders is an underutilized substance that may be used to translate genetic and/or preclinical studies ([@B23]; [@B48]; [@B49]; [@B88]). A study using postmortem brain samples showed decreased expressions of Keap1 and Nrf2 in the parietal cortex from patients with MDD and bipolar disorder compared to control group ([@B100]). A recent study showed the reduced (-21%) expression of Nrf2 in the dorsolateral prefrontal cortex from MDD patients ([@B45]). These results suggest that decreased Keap1-Nrf2 signaling plays a key role in the pathophysiology of mood disorders such as MDD and bipolar disorder ([@B100]).

Single Nucleotide Polymorphisms in the *Nrf2* Promoter Gene in Humans
=====================================================================

The NRF2 activity in humans is regulated through protein stabilization, primarily by KEAP1, but is also regulated at the transcriptional level ([@B86]). In humans, a *NRF2* promotor single nucleotide polymorphism (SNP: rs6721961) located 617 bp by upstream from the transcription start site lowers the level of *NRF2* transcription ([@B87]; [@B86]; **Figure [3](#F3){ref-type="fig"}**). Luciferase assays showed that polymorphism at position -617 (C to A) affect basal levels of NRF2, thereby resulting in attenuation of ARE-mediated gene transcription ([@B46]; **Figure [3](#F3){ref-type="fig"}**). Interestingly, subjects who possess this SNP are more susceptible to acute lung injury and related diseases ([@B46]), and this SNP is also found to correlate with the incidence of non-small cell lung cancer ([@B78]). In addition, ethnic difference of this SNP is also reported ([@B46]). Therefore, it is of interest to study whether this SNP can affect susceptibility to mood disorders.

![SNP (rs6721961) in the promotor region of *NRF2* gene. The SNP (rs6721961) in the promotor of *NRF2* gene alters the transcription level of *NRF2* gene, resulting in alterations in the expression of *NRF2* target genes. The NRF2/sMAF (small MAF) protein complex regulates the oxidative stress response by occupying *cis*-acting enhancers containing an antioxidant response element (ARE). A slight modification of [@B86].](fphar-09-01182-g003){#F3}

Depression-Like Phenotypes in *Nrf2* KO Mice
============================================

Serum levels of TNF-α, IL-6, IL-10, and IL-1β in the *Nrf2* KO mice were significantly higher than those of wild-type (WT) mice, suggesting that *Nrf2* KO mice have inflammation ([@B96]). In the tail-suspension test (TST) and forced swimming test (FST), the immobility times of TST and FST in *Nrf2* KO mice were higher than those of WT mice. In the 1% sucrose preference test (SPT), the sucrose preference of *Nrf2* KO mice was lower than that of WT mice, suggesting that *Nrf2* KO mice have anhedonia. Furthermore, brain-derived neurotrophic factor (BDNF) and its receptor TrkB signaling in the CA3, DG and PFC of *Nrf2* KO mice were lower than those of WT mice. Moreover, protein levels of AMPA receptor 1 (GluA1) and postsynaptic density protein 95 (PSD-95) in the CA3, DG, and PFC of KO mice were lower than those of WT mice. Interestingly, 7,8-dihydroxyflavone (a TrkB agonist) produced antidepressant effects in *Nrf2* KO mice, by stimulating TrkB in the PFC, CA3, and DG ([@B96]). Furthermore, the anti-inflammatory drug rofecoxib reversed depression-like behaviors in *Nrf2* KO mice ([@B44]). In addition, chronic treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine increased BDNF in cortex and hippocampus of corticosterone-treated *Nrf2* KO mice ([@B52]), suggesting that Nrf2 signaling contributes to fluoxetine-induced neuroprotection. These all findings suggest that Nrf2 plays a key role in the depression-like phenotypes in rodents through potent anti-inflammatory action. Collectively, it is likely that *Nrf2* KO mice show depression-like phenotypes through inflammation, decreased BDNF-TrkB signaling and synaptogenesis (**Figure [5](#F5){ref-type="fig"}**; [@B96]).

In contrast, [@B5] reported that *Nrf2* KO mice did not display a depression-like phenotype although the KO mice were characterized by oxidative stress and by anatomical alterations in hippocampal CA3 pyramidal cells. However, when exposed to 3 weeks of chronic mild stress, *Nrf2* KO mice developed depression-like phenotypes which were prevented by pretreatment with antioxidant ([@B5]). This study also suggests the role of Nrf2-dependent persistent oxidative stress in stress-induced vulnerability to depression.

Antidepressant Effects of Nrf2 Activators in the Rodent Models of Depression
============================================================================

When lipopolysaccharide (LPS), the bacterial endotoxin, is administered to rodents, depression-like behaviors are observed 24 h after inflammation ([@B7]; [@B61]; [@B99]; [@B104]). Pretreatment with antidepressants, such as SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs), can prevent depression-like behavior and alterations in serum pro-inflammatory cytokines, such as TNF-α, induced by LPS administration ([@B63]; [@B94]; [@B11]). These all findings suggest that inflammation is associated with depression, and that anti-inflammatory drugs could ameliorate depressive symptoms in patients with depression.

Pretreatment with SFN significantly blocked an increase in the serum TNF-α level after a single administration of LPS ([@B103]). Furthermore, SFN significantly potentiated increased serum levels of IL-10 after LPS administration. SFN attenuated an increase of the immobility time of TST and FST after LPS administration. In addition, SFN recovered to control levels for LPS-induced alterations in the proteins such as BDNF, PSD-95 and GluA1, and dendritic spine density in the brain regions ([@B103]). Furthermore, TBE-31 or MCE-1 attenuated an increase in serum levels of TNF-α after LPS administration. Administration of TBE-31 or MCE-1 attenuated an increase in the immobility time of TST and FST after LPS administration ([@B95]).

Pretreatment with SFN attenuated the decreased social avoidance time and sucrose preference in CSDS model. Furthermore, SFN could attenuate the decreased levels of Nrf2 and Keap1 proteins in the PFC and hippocampus of mice with depression-like phenotype ([@B96]). [@B36] reported that decreased Keap1-Nrf2 signaling in the PFC, hippocampus and skeletal muscle may contribute to anhedonia susceptibility after spared nerve injury (SNI), and that SFN exerts beneficial effects in SNI rats by normalization of decreased Keap1-Nrf2 signaling. These results suggest that Keap1-Nrf2 signaling plays a role in depression, and that SFN is prophylactic compound which can stimulate Keap1-Nrf2 signaling pathway ([@B96]; [@B103]; [@B36]). Taken all together, it is likely that the Nrf2 activators such as SFN, TBE-31, and MCE-1 might be potential prophylactic or therapeutic drugs for inflammation (or stress)-related depression ([@B95],[@B96]; [@B104], [@B103]; [@B36]).

Effects of Dietary Intake of SFN Precursor in the CSDS Model of Depression
==========================================================================

SFN is produced in the body from its precursor glucoraphanin which is involved in cruciferous vegetables. Previously, we demonstrated that dietary intake of 0.1% glucoraphanin --rich food during juvenile and adolescence prevented phencyclidine-induced cognitive deficits and loss of parvalbumin (PV)-positive cells in the PFC at adulthood ([@B74]). Furthermore, we also reported that dietary intake of 0.1% glucoraphanin --rich food during juvenile and adolescence prevented the onset of psychosis in the adult offspring after maternal immune activation ([@B47]). These findings suggest that dietary-intake of glucoraphanin-rich vegetables in high-risk psychosis subjects might prevent the transition to psychosis in young adulthood ([@B21]; [@B74]; [@B47]).

Interestingly, dietary intake of 0.1% glucoraphanin containing food during juvenile and adolescent stages could prevent the depression-like phenotype in adulthood after CSDS ([@B96]). Thus, the dietary intake of 0.1% glucoraphanin containing food during juvenile and adolescent periods could confer stress resilience in adulthood.

Clinical Study of SFN in Patients with Healthy Subjects, and Neurodevelopmental Disorders
=========================================================================================

[@B71] reported that SFN increased blood glutathione (GSH) levels in healthy human subjects following 7 days of daily oral administration. Furthermore, a significant positive correlation between blood and thalamic GSH post- and pre-SFN treatment ratios was observed, in addition to a consistent increase in brain GSH levels in response to treatment. This study suggests the value of exploring relationships between peripheral GSH and clinical/neuropsychological measures, as well as the influences SFN has on functional measures that are altered in neuropsychiatric disorders.

A randomized, double-blinded, placebo-controlled study showed that SFN-rich broccoli sprout extract could improve social interaction, abnormal behavior and verbal communication in young male subjects with autism spectrum disorder ([@B76]; [@B42]). In addition, a pilot study showed that supplementation with glucoraphanin-rich broccoli sprout extract for 8 weeks was effective in treating cognitive impairment in medicated patients with schizophrenia ([@B73]). Collectively, it is likely that SFN would be potential therapeutic compound for neurodevelopmental disorders.

Role of Nrf2 in the Mechanisms of Antidepressant Action for Other Potential Compounds
=====================================================================================

Cilostazol is used in the treatment of the symptoms of intermittent claudication in patients with peripheral vascular disease. In the chronic restraint stress (CRS) model, cilostazol prevented depressive-like behaviors ([@B2]). Furthermore, cilostazol modulated the Nrf2 protein and heme oxygenase-1 and NAD(P)H: quinone oxidoreductase-1 gene expression in the hippocampus of CRS rats. These findings suggest that cilostazol has the prophylactic antidepressant effect by preventing oxidative stress by stimulation of redox defense mechanisms mediated through the Nrf2 pathway ([@B2]).

Dl-3-n-Butylphthalide (NBP), a small molecule compound extracted from the seeds of *Apium graveolens*, was approved by the State Food and Drug Administration of China for treating ischemic stroke ([@B1]). NBP attenuated the depression-like behaviors and increased expression of pro-inflammatory cytokines (e.g., IL-1β and IL-6) in rats. In addition with the anti-inflammation action, NBP reduced LPS-induced oxidative stress reactions in the hippocampus and enhanced Nrf2-targeted signals ([@B93]).

A randomized, double-blind, placebo-controlled trial showed that NBP showed greater effects than placebo on Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) and clinician's interview-based impression of change plus caregiver input (CIBIC-plus). NBP-related adverse events were uncommon and primarily consisted of mild gastrointestinal symptoms ([@B28]). Therefore, it is of interest to examine whether NBP can improve depressive symptoms in depressed patients.

Nrf2 Inhibitors
===============

Compared with Nrf2 activators, the development of Nrf2 inhibitors is in its infancy ([@B86]). For example, cancers with persistent activation of Nrf2 exhibit high dependency on Nrf2 function for drug resistance and cell proliferation ([@B86]). The plant-based product brusatol (**Figure [4](#F4){ref-type="fig"}**) decreases the protein levels of Nrf2 and sensitizes cancer cells to chemotherapy and radiotherapy ([@B68]). Another Nrf2 inhibitor halofuginone (**Figure [4](#F4){ref-type="fig"}**) is a synthetic halogenated derivative of febrifugine, a natural quinazolinone alkaloid which can be found in the Chinese herb *Dichroa febrifuga*. Halofuginone exerts a chemosensitizing effect on cancer cells exhibiting constitutive Nrf2 stabilization ([@B80]). In addition, [@B75] demonstrated that ML385 \[*N*-\[4-\[2,3-dihydro-1-(2-methylbenzoyl)-1H-indol-5-yl\]-5-methyl-2-thiazolyl\]-1,3-benzodioxole-5-acetamide\] (**Figure [4](#F4){ref-type="fig"}**) is a novel and specific Nrf2 inhibitor. Therefore, it is of interest to study whether these Nrf2 inhibitors can affect depression-like phenotypes in rodents.

![Chemical structure of Nrf2 inhibitors (brustal, halofuginone, ML-385).](fphar-09-01182-g004){#F4}

Conclusion Remarks and Future Perspective
=========================================

Rodents with depression-like phenotype have higher blood levels of pro-inflammatory cytokines, suggesting that inflammation plays a role in depression-like phenotype in rodents. Furthermore, rodents with depression-like phenotype have lower expression of Keap1 and Nrf2 in the PFC and hippocampus ([@B96]; [@B103]). Interestingly, we found decreased expression of Keap1 and Nrf2 in the parietal cortex from patients with MDD and bipolar disorder ([@B100]). Given the essential role of BDNF-TrkB signaling in depression ([@B58]; [@B24]; [@B13]; [@B20]; [@B104]), inflammation (or stress)-induced reduction of Keap1-Nrf2 system may contribute to decreased BDNF-TrkB signaling and synaptogenesis, resulting in depression-like phenotypes (**Figure [5](#F5){ref-type="fig"}**). It is noteworthy that TrkB agonist 7,8-DHF has antidepressant effects in *Nrf2* KO mice ([@B96]), LPS-treated mice ([@B99]) and CSDS susceptible mice ([@B102]), suggesting a possible link between Keap1-Nrf2 system and BDNF-TrkB signaling ([@B52]; [@B96]; [@B103]; [@B36]; **Figure [5](#F5){ref-type="fig"}**).

![Proposed hypothesis of role of Keap1-Nrf2 system in depression. Inflammation causes decreases of Keap1 and Nrf2 expression in the prefrontal cortex and hippocampus. Subsequently, inflammation-induced decreases in Keap1 and Nrf2 proteins can cause the decreased BDNF-TrkB signaling and synaptogenesis, resulting in depression-like phenotype. TrkB agonists might have antidepressant actions. Dietary intake of glucoraphanin (or SFN) in cruciferous vegetables during early adolescence may confer to stress resilience at adulthood whereas poor nutrition may play a role in the onset of depression by stress or inflammation.](fphar-09-01182-g005){#F5}

Nutritional status during early adolescence stage might have a great impact on the onset and severity of psychiatric diseases in adulthood ([@B65]; [@B62]). Over the past decade, there has been increasing interest in the potential benefits of early intervention for psychiatric disorders such as depression ([@B65]; [@B62]; [@B70]; [@B6]).

Preclinical findings suggest that dietary intake of glucoraphanin during juvenile and adolescence can protect against depression-like behaviors after CSDS or LPS administration ([@B96]; [@B103]), indicating prophylactic effects of glucoraphanin for depression. Thus, dietary intake of glucoraphanin (or SFN) during juvenile and adolescence might confer stress resilience at adulthood (**Figure [5](#F5){ref-type="fig"}**). Therefore, it is possible that dietary intake of glucoraphanin (or SFN) during childhood and adolescence stages could prevent the onset of depression in humans during adulthood. Since patients with mood disorder have high relapse rate, dietary intake of glucoraphanin (or SFN) may prevent or minimize relapse from remission, induced by inflammation and/or stress in depressed patients.
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